Feeds:
Posts
Comments

Posts Tagged ‘Eli Lilly and Company’

Wasn’t able to get to a “Top Three” yesterday, as I was attending a (VERY interesting) real-time communications conference in NYC. Blog post coming on that. Meanwhile…

Pfizer, Pfizer, Pfizer. 800 researcher jobs being axed. 100 experimental drugs being sold off in a closeout sale. And, a new (outsider – former General Mills CEO) addition to the board of directors.

Forest gets approval for new fibromyalgia drug Savella. The safety and efficacy of Savella was established in two U.S. pivotal Phase III clinical trials involving over 2,000 patients with fibromyalgia, the companies said.

Eli Lilly handing over 1.42 billion to resolve Zyprexa probes. Eli Lilly and Co said it will pay about $1.42 billion to settle both criminal and civil investigations related to the marketing of its antipsychotic drug Zyprexa and has agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act.

Live and in-person – the next conference I’ll be attending is the ePharma Summit in Philadelphia, Feb. 9-11. Here’s the scoop.

—–

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Reblog this post [with Zemanta]
Advertisements

Read Full Post »

Some surprises in the new diabetes guidelines issue by the American Diabetes Association and European Association for the Study of Diabetes…more

Speaking of diabetes – we’re paying a lot more over the last few years!

And, a triple dose of diabetes news, including bad news for Avandia.

Medtronic exec says devices are finished?????? Now that’s an interesting PR move!

FDA accepts priority review of expanded Erbitux label.

My favorite headline of the week. Type-1 Diabetes Not So Much Bad Genes as Good Genes Behaving Badly, Stanford Research Shows.

Novo: we have cash and we know how to use it – Novo Nordisk A/S is earmarking as much as $2 billion for takeovers in the next 12 months as the financial crisis forces cash-strapped biotechnology companies onto the market, Chief Financial Officer Jesper Brandgaard said.“We are more or less able to finance in cash acquisitions within the $1 billion to $2 billion range,” Brandgaard said in a phone interview from Copenhagen. “We think there will be opportunities in biotech which we haven’t seen before.”…more

Meet the new team at Pfizer.

Ortho Clinical Diagnostics gets a biological tester approved.

Big Crestor study results could be “game changer” – A forthcoming AstraZeneca study could dramatically increase the market for cholesterol-lowering drugs, otherwise known as statins, which are already pharma’s biggest success story, Forbes writes…more

New “Superbug” antibiotics on the way? – Two experimental antibiotics appear to work safely against an increasingly common and dangerous form of infection called methicillin-resistant Staphylococcus aureus or MRSA, researchers said on Sunday…more

Schering’s new anesthesia-recovery drug looking good – An experimental drug worked many times faster than a standard treatment in helping surgery patients recover from anesthesia, according to a just-published study funded by its developer, Schering-Plough Corp…more

Lashes. Lovely lashes. And an eye-color change, too. Welcome to Lumigan.

$1.4 Billion – “not meaningful” to Eli Lilly. Huh?

Some promising Phase III clinical trial results – Novartis biologic shows great efficacy on a rare autoinflammatory disease. And, Merck‘s Isentress looks good on treatment-naive HIV patients.

Apidra approved for pediatric diabetes – Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra® (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus…more

U.S. drug sales growing much more slowly than forecast – The number crunchers at IMS Health just cut their estimate for growth of U.S. drug sales to 1% to 2% this year– way down from the 4% to 5% they’d previously forecasted, the WSJ reportsmore

BusinessWeek chats with a few pharma CEOs – As part of a package of stories about big pharma, BusinessWeek grabbed the ceo at four drugmakers – Pfizer’s Jeff Kindler; Bristol-Myers Squibb’s Jim Cornelius; Lilly’s John Lechleiter and Roche’s Severin Schwan – to discuss the varied and vexing problems the industry faces. Here are a few of their comments…more

Reblog this post [with Zemanta]

Read Full Post »

Is Eli Lilly the “mystery suitor” for ImClone? – Eli Lilly & Co. is in advanced talks to buy cancer-drug developer ImClone Systems for $70 a share, or $6.1 billion, The Wall Street Journal reported on Thursday, citing people familiar with the matter…more And why the big interest in ImClone? Business Week says “it’s the pipeline.”

Prasugrel delayed…again – Once again, the FDA has delayed its approval of prasugrel, a blood thinner that Lilly and its partner, Daiichi Sankyo, have been hoping will one day compete against Plavix, which is marketed by Bristol-Myers Squibb and Sanofi-Aventis…more

Judge: Amgen yes, Roche no – A federal judge in Boston ruled the drugmaker infringed on Amgen’s patents with its Mircera anemia med, essentially upholding a preliminary decision issued in February. The order by US District Court Judge William Young deals a big setback to Roche, which already cut costs after its plans to market Mircera flopped…more

Credit crunch? Roche says, nah…we still want Genentech – The market isn’t so sure Roche can raise the money to buy Genentech, but Roche seems pretty confident…more

Encouraging data for Pfizer’s HIV drug – The Pfizer Inc. AIDS drug maraviroc helps thwart the HIV virus in nearly half of people who have developed resistance to other treatments, according to two related studies published on Wednesday…more

Pfizer bailing out of some therapeutic areas for drug development – Pfizer Inc  will drop efforts to develop medicines for heart disease, as part of a reshuffling of its research activities that the pharmaceutical giant plans to announce on Tuesday, according to a Wall Street Journal report. Pfizer also is expected to announce it will abandon therapies for obesity and bone health to focus on more lucrative areas such as cancer and Alzheimer’s disease, WSJ said on its online site…more More here from Forbes

The Pfizer pipeline: current status – Even as Pfizer is bailing out of drug research for heart disease, the company’s late-stage pipeline has increased to 25 projects from 16 in the past six months…more

A potential Viagra competitor derived from a plant with…well, a pretty bizarre name!

Merck drops experimental weight-loss pill – The drugmaker made the decision after spending months reviewing trials showing the taranabant obesity pill caused psychiatric side effects. You may recall that a late-stage trial showed the drug didn’t yield the hoped-for weight loss of 5 percent at the 2 mg dose the drugmaker hoped to sell…more

Daiichi Sankyo cleared to buy Indian drugmaker Ranbaxy.

From PharmExecspecialty drug prices spiking.

Big settlement by Cephalon on out-of-bounds marketing practices. Whistleblower vindicated.

What’s $1.2 billion between competitors? Ask Boston Scientific

Reblog this post [with Zemanta]

Read Full Post »

Prasugrel review extended – Daiichi Sankyo Company, Limited, and Eli Lilly and Company said that the U.S. Food and Drug Administration (FDA) has extended the review period for the prasugrel new drug application (NDA) based on supplemental information provided during the review period…more

Heart trials for diabetes medicines? – The agency wants its Endocrinologic and Metabolic Drugs Advisory Committee to decide whether clinical trials to evaluate cardiovascular risks should be undertaken before the meds are approved or after marketing begins and the drugs are used by the population at large…more

Paxil and pregnancies – Much of the hoopla one reads about the controversial antidepressant concerns the risk of suicide and the extent to which the drugmaker disclosed – or did not disclose – meaningful clinical trial data…more

Doctors under the Influence?

Breathing easier at Merck and Schering? – Could it be? Are they getting a divorce over Vytorin? No, sorry to excite you. But the drugmakers are ending their respiratory joint venture and their eight-year effort to market a combination of their Claritin and Singulair medications, which are used to treat allergic rhinitis…more

Analyst takes up news space with BMS conjecture – The drugmaker looks increasingly attractive and a sale is a “distinct possibility,” according to Tim Anderson, a pharma analyst at Sanford Bernstein…more

Pharma’s sinking reputation – The latest Harris Interactive poll that examines American attitudes toward corporate America offers a sobering view of and for the pharmaceutical industry. Only 26 percent of Americans view the industry favorably…more

Can’t make this stuff up – A drug developed using nanotechnology and a fungus that contaminated a lab experiment may be broadly effective against a range of cancers, U.S. researchers reported on Sunday…more

Sweet home Alabama – A state court jury decided the two drugmakers defrauded Alabama in a long-running Medicaid drug pricing scheme and ordered them to pay more than $114 million in damages, the Associated Press reports…more

Pfizer rocking the CME funding world – In what may be a first, a drugmaker will still support continuing medical education courses at academic institutions, teaching hospitals and those supported by medical societies, but no longer directly support CME courses offered by for-profit medical-education and communication companies, Dow Jones reports…more

Xience (drug-eluting stent from Abbott) gets approval.

They do pass laws in D.C., after all – Earlier this year, the city became the first in the country to license sales reps, whose licenses can be revoked if their activities are deemed fraudulent. The bill was passed in hopes of enforcing good business practices on people who have undue influence over docs, and therefore patients…more

Zemanta Pixie

Read Full Post »

Cymbalta approved for Fibromyalgia – The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company announced today…more

Takeda’s Actos may help prevent diabetes – Actos, a pill to treat diabetes, can prevent development of the disease in people with early symptoms, U.S. researchers reported…more

Amylin’s once-weekly Byetta looks promising for lowering blood sugar – Amylin Pharmaceuticals Inc said on Monday that a once-weekly version of its Byetta type 2 diabetes medicine led to additional improvements in blood sugar levels over the currently available drug that must be injected twice a day…more However, their stock was pounded after many positive news reports of competitive drugs.

Ranbaxy up for grabsDaiichi makes bid. Also, strikes deal with Pfizer over generic Lipitor.

Elan/Wyeth experimental Alzheimer’s drug continues to progress in clinical trials – A closely watched Phase II study of an experimental Alzheimier’s drug being developed by Elan and Wyeth shows the med appears to be effective in some patients. Known as bapineuzumab, the drug failed to achieve statistically significant results in the primary outcomes, but managed to do so in subgroups lacking a higher genetic risk to develop the disease…more

J&J, Red Cross, call it quits on legal fight – The lawsuits had an absurdist, has-it-really-come-to-this quality about them. Johnson & Johnson and the Red Cross — Band-Aids and baby powder, blood drives and disaster relief — were suing each other over the rights to the red cross emblem that both had long shared. Now, after getting most of its suit against the Red Cross tossed out by a judge, Johnson & Johnson has picked up its legal toys and gone home. The company said today that it is dismissing its remaining claims against the august nonprofit. And the Red Cross, for its part, threw out its counterclaims against J&J. The companies’ statement is online here more

FDA and Genentech in a staredown – Last year, Genentech caused a ruckus by restricting distribution of its Avastin med to compounding pharmacies, which were repackaging and selling the drug to opthalmologists for treating wet macular degeneration. Unlike Avastin, Genentech’s similar, but newer Lucentis was approved to treat the malady, but at $2,000 a dose will cost about 40 times as much…more

Cancer drug Gleevec may help with strokes? Very cool – A highly effective leukemia pill may reduce complications and boost the effectiveness of a treatment for the most common type of stroke, an international team of researchers said on Sunday. Studies in mice showed giving Gleevec or imatinib, a drug made by Novartis AG, significantly reduced bleeding in the brain associated with the clot-busting drug known as tissue plasminogen activator or tPA…more

Millennium/Takeda’s Velcade gets expanded approval – Takeda Pharmaceutical Co, Japan’s largest drugmaker, won U.S. approval to promote its cancer drug Velcade for earlier treatment of multiple myeloma, the company said on Friday…more

Zemanta Pixie

Read Full Post »